Safety of ublituximab – what do we currently know? Review article
Article Sidebar
Main Article Content
Abstract
Ublituximab is one of the newest disease-modifying drugs for multiple sclerosis. It is a monoclonal antibody directed against CD20, a molecule that has become an important therapeutic target in multiple sclerosis in recent years. Although the mechanism of action of ublituximab has been widely described, a complete safety assessment, as with any new drug, relies not only on clinical trial data but also requires a detailed analysis of information from real-world clinical practice. This is clearly only possible over time and with the drug being used in a broad population of patients whose clinical characteristics, including age, comorbidities, and concomitant medications, differ from those required for clinical trial participants. This article presents the current state of knowledge on ublituximab safety based on clinical trials, including the open-label extension phase, and observations from everyday clinical practice. Furthermore, based on available data, areas requiring further research are identified.
Article Details
Copyright ? by Medical Education. All rights reserved.
References
2. Preziosa P, Brescia Morra V, Capobianco M et al. Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion. J Neurol. 2025; 272: 707. https://doi.org/10.1007/s00415-025-13442-0.
3. European Medicines Agency. Briumvi.
4. Charakterystyka Produktu Leczniczego. Briumvi (wersja z 8.10.2025 r.).
5. Mirowska-Guzel D, Niedzielko M, Kruk M. Wybrane elementy informowania o ryzykach związanych z farmakoterapią. In: Komunikacja medyczna – wyzwania i źródła inspiracji. Doroszewska A, Chojnacka-Kuraś M, Jankowska A (eds.). Wydawnictwa Uniwersytetu Warszawskiego, Warszawa 2023: 99-115.
6. Steinman L, Fox E, Hartung H-P et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022; 87(8): 704-14. https://doi.org/10.1056/NEJMoa2201904.
7. Cree BAC, Fox E, Hartung H-P. Five Years of Ublituximab in Multiple Sclerosis ULTIMATE I and II Open-Label Extension Study. JAMA Neurol. 2026; 83(4): 348-58.
8. Palmeira P, Quinello C, Silveira-Lessa AL et al. IgG Placental Transfer in Healthy and Pathological Pregnancies. Clin Dev Immunol. 2012; 2012: 985646. https://doi.org/10.1155/2012/985646.
9. FDA, rejestr ciąż w bazie Clinicaltrials.gov. Briumvi, NCT06433765.
10. EMA rejestr ciąż. Briumvi .
11. Protokół rejestru ciąż dla ublituksymabu ..
12. Protokół badania oceniającego stężenie ublituksymabu w mleku matki Clinicaltrials.gov. NCT06143514.
13. Ho CS, Tan LL, Chan CL. Introduction to Risk Management Plans in the Singapore Context. Singapore Med J. 2019; 60(9): 483-6.
14. Plan zarządzania ryzykiem. Briumvi (wersja z 15.12.2023 r.).
15. Cao J, Shen Q, Zou Y. A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration’s adverse event reporting system databases. Front Immunol. 2026; 17: 1738185. https://doi.org/10.3389/fimmu.2026.1738185.
16. Luo S, Feng Y, Huang Z et al. Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system. Int J Clin Pharm. 2025; 47(6): 2017-26. https://doi.org/10.1007/s11096-025-02019-6.
17. Mirowska-Guzel D, Nojszewska M, Jaroszewicz J et al. Herpes zoster prevention in multiple sclerosis and neuromyelitis optica spectrum disorders. Neurol Neurochir Pol. 2025; 59(1): 1-5. https://doi.org/10.5603/pjnns.102908.
18. Wimmer I, Tietz S, Nishihara H et al. PECAM-1 stabilizes blood-brain barrier integrity and favors paracellular T-cell diapedesis across the blood-brain barrier during neuroinflammation. Front Immunol. 2019; 10: 711. https://doi.org/10.3389/fimmu.2019.00711.